Get the Stockscreener App
24.91
0.95%
-0.24
Pre-market:
24.83
-0.08
-0.32%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.91, with a volume of 44.84M.
It is down -0.95% in the last 24 hours and up +2.22% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.15
Open:
$24.835
24h Volume:
44.84M
Relative Volume:
1.11
Market Cap:
$141.97B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
19.10
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-0.40%
1M Performance:
+2.22%
6M Performance:
-5.79%
1Y Performance:
+4.62%
1-Day Range:
$24.55
$24.98
1-Week Range:
$24.44
$25.50
52-Week Range:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.91 | 140.61B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,154.97 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.82 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
257.41 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.79 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer shares may move 3% around Aug. 4 earnings release - Investing.com
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Is Wall Street Bullish or Bearish on Pfizer Stock? - Barchart.com
Pfizer (NYSE:PFE) Shares Gain Pre-Earnings as 7% Dividend Undergoes Cash-Flow Scrutiny - TechStock²
Pfizer price shows cautious gainsForecast today28-07-2026 - Economies.com
Quantinuum, NVIDIA Corporation, and Pfizer Inc Transformer Models Now Generate Quantum Circuits for Molecular Models - Quantum Zeitgeist
Pfizer Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
PFIZER: Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs - TradingView
Pfizer Inc Lobbyists, 2026 - OpenSecrets
City stops construction at downtown office-to-resi conversion after Pfizer project scare - Crain's New York Business
Can Pfizer (NYSE:PFE) Turn Its Cancer & Obesity Reset Into A New Chapter? - Kalkine Media
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine - marketscreener.com
Pfizer: Calling The BottomThe Patent Cliff Is Real, But The Valuation Has Fallen Too Far - Seeking Alpha
Former Pfizer HQ Evacuation Puts Office Conversions Under Structural Scrutiny - StreetInsider
Pfizer (NYSE:PFE) edges up as low-multiple pharma draws value notice this week - Kalkine Media
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Is - Benzinga
Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative? - Yahoo Finance
Pfizer: Board meeting tomorrow; Shares decline 0.62 percent - TradingView
Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer? - simplywall.st
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
PFE Stock Quote Price and Forecast - CNN
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. - Yahoo Finance
Pfizer stock stabilizes as oncology and vaccine pipeline shapes outlook - AD HOC NEWS
Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win - Law360
Pfizer’s ex-comms leader joins Vantage Data Centers - Medical Marketing and Media
Pfizer stock trades steadily as recent earnings and pipeline shape investor sentiment - AD HOC NEWS
How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push - simplywall.st
Samsung, Celltrion Join Nectin-4 ADC Race, Challenging Pfizer's Padcev Dominance - finance.biggo.com
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer - The Globe and Mail
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit. - JD Supra
Pfizer building incident pits banner project with a conversion pitfall - The Real Deal
Pfizer (NYSE:PFE) Leads Healthcare Focus on Balance-Sheet Strength - Kalkine Media
Curated Wealth Partners LLC's Pfizer Inc(PFE) Holding History - GuruFocus
Pfizer stock trades steady as Pfizer India posts stronger FY 2024 earnings - Ad-hoc-news.de
Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access - Bloomberg Law News
Pfizer stock steadies as investors weigh pipeline progress and recent earnings - Ad-hoc-news.de
Pfizer Prevnar 20 by Pfizer Inc.broader adult protection in one syringe - Ad-hoc-news.de
Pfizer Inc (0Q1N) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
What Makes Pfizer (NYSE:PFE) Stand Out in the S&P 500? - Kalkine Media
Pfizer (PFE) Secures Priority Review for Talzenna in Prostate Ca - GuruFocus
Pfizer’s prostate cancer drug combination gets US FDA priority review - 1470 & 100.3 WMBD
Pfizer's prostate cancer drug combination gets US FDA priority review - Reuters
FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use - Investing.com
Pfizer trial: TALZENNA combo cut progression-or-death risk 52% - Stock Titan
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck - HIT Consultant
Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology - simplywall.st
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Pfizer (NYSE:PFE) Oncology Growth Faces A Major Valuation Test - Kalkine Media
Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones - Ad-hoc-news.de
Sanofi reprimanded for disparaging Pfizer’s RSV vaccine - Fierce Pharma
Prevnar 20 by Pfizerbroader pneumococcal protection for adults - Ad-hoc-news.de
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
1.09%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):